Questcor (QCOR) is a biotechnology company focused on providing prescription drugs for central nervous system disorders. It offers ''Acthar'', the sole revenue driving drug, which treats patients with multiple sclerosis and infantile spasms. Acthar, in the first quarter of 2013, reported $126 million in revenue, compared to the company's total revenue of $135.1 million. This drug accounts to 93% of the total revenue. Its key areas of focus are neurology, nephrology, and rheumatology. The company makes research initiatives on a variety of medical conditions that are not completely controlled or cured with existing drugs on the market.
Acthar will bring additional upside on the revenue
Questcor's Acthar has received FDA approval for 19 separate indications in...
Only subscribers can access this article, which is part of the PRO research library covering 3,623 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: